#tweetorial 🧵
🚩Metabolism and Acute Myeloid Leukemia
(1/23)
➡️📈🔎Increased attention over the last decade on the metabolic perturbations in AML
➡️Potential therapeutic implications – with ‘druggable’ targets
(2/23)
➡️🗒️📌Summary of recent concepts
🔊IT IS ALL HAPPENING IN THE MITOCHONDRIA
👉📈🏹Increase potential of targeting the mitochondria
👉🦀Anti-cancer agents specifically targeting cancer cell mitochondria are referred to as 'mitocans'
(3/23)
➡️Metabolic adaptions of AML cells
AML is a 🦀cancer derived from the myeloid lineage of blood🩸cells, characterized by overproduction of malignant cells.
(4/23)
🧩🧩Warburg or Mitochondria respiration - Acute Myeloid leukemia❓❓
👉Many cancer cells utilize aerobic glycolysis to meet the anabolic demands of cell growth and proliferation, also known as the ‘Warburg effect"
(5/23)
👉Some subsets of AML cells have been found to be disproportionately reliant on the mitochondrial function to support cell survival
(6/23)
➡️BCL-2 inhibition🎯targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells.
(7/23)
➡️AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells
👉Human AML LSCs display high FIS1 expression and unique mitochondrial morphology.
(8/23)
➡️Nicotinamide Metabolism Mediates Resistance to Venetoclax in🔁Relapsed Acute Myeloid Leukemia🩸Stem Cells
👉Nicotinamide metabolism is increased upon relapse in leukemia stem cells
👉🎯Targeting nicotinamide metabolism eradicates relapsed leukemia stem cells
(9/23)
➡️🎯Targeting Glutamine Metabolism and Redox State for Leukemia Therapy 💊
👉The use of a glutaminase inhibitor (drug 1, e.g., CB-839) blocks glutamine metabolism and production of antioxidant GSH and 👇
(10/23)
👉Makes leukemia cells vulnerable to a pro-oxidant agent (drug 2, e.g., ATO or HHT), leading to super induction of mitoROS and subsequent leukemia cell death ☠️via apoptosis.
(11/23)
➡️Inhibition of Amino Acid Metabolism Selectively Targets🎯 Human👫Leukemia Stem Cells
👉LSCs catabolize amino acids into TCA-cycle intermediates, making LSCs⚡️highly dependent on amino acid metabolism for OXPHOS and survival
(12/23)
➡️Cysteine depletion targets leukemia stem cells through 🔽inhibition of electron transport complex II
👉Loss of SDHA glutathionylation impairs ETC II activity, thereby inhibiting oxidative phosphorylation, reducing the production of ATP, and leading to LSC death.
(13/23)
➡️Venetoclax with Azacitidine Disrupts Energy Metabolism and Targets Leukemia Stem Cells in Acute Myeloid Leukemia Patients
👉Glutathionylation, a post-translation modification, has been shown to increase ETC complex II activity.
(14/23)
➡️Targeting mitochondrial structure sensitizes acute myeloid leukemia to Venetoclax treatment
👉🎯Targeting the mitochondrial CLPB sensitizes AML cells to Venetoclax treatment💊.
(15/23)
➡️Systematic Dissection of the Metabolic-Apoptotic Interface in AML🪞Reveals Heme Biosynthesis to Be a Regulator of Drug Sensitivity👇
(16/23)
👉🔽Reduction of heme biosynthesis ⚡️potentiates apoptosis through the loss of ETC activity, resulting in baseline depolarization of the mitochondrial membrane and an 📈increased propensity to undergo apoptosis.
(17/23)
➡️An 🔽inhibitor of oxidative phosphorylation exploits 🦀cancer vulnerability
👉Glycolysis-deficient and AML tumour cells are sensitive to OXPHOS inhibition and 👇
(18/23)
👉IACS-010759 (Complex-I ETC) robustly inhibited proliferation and induced apoptosis in models of brain cancer and acute myeloid leukemia (AML) reliant on OXPHOS, likely owing to a combination of energy depletion and impaired nucleotide biosynthesis.
(19/23)
➡️Very long-chain⛓️fatty acid metabolism is required in acute myeloid leukemia 👇
(20/23)
👉Genetic 🧬attenuation or pharmacological🔽 inhibition of VLCAD hindered mitochondrial respiration and FAO contribution to the tri-carboxylic acid cycle 🌀, resulting in 📉decreased viability, proliferation, clonogenic growth, and AML cell engraftment.
(21/23)
🗝️🗝️Summary
1⃣📌Substantial evidence of literature exists delineating the interaction between AML metabolism, leukemia cell survival, response to existing therapies 💊 and novel therapeutic strategies.
(22/23)
2⃣📌Different metabolic pathways are involved in intracellular metabolic reprogramming depending on the genetic characteristics of AML cells.
(23/23)
3⃣📌Metabolic pathways fuelling OXPHOS appear to be critical for AML cell survival and will potentially become therapeutic targets to improve outcomes for patients with AML.
🛑END OF TUTORIAL!!
🙏Please RT and👍Like if you enjoyed reading this :)
🏃🏃♂️🏃♀️Follow us for more such #tweetorial
🧵🧵
1/18
We at HCC are so proud of our team and participating centers. 6 abstracts of our collective work have been accepted for #ASH22. If you wish to be a part of this movement either as an individual or as a participating institution, do visit us at hemecancer.org/membership.php
2/18
#2976 Prognostic Factors and Outcomes of Adolescent and Adult Burkitt Lymphoma and Leukemia from a Low-Middle Income Country: An Experience from Hematology Cancer Consortium ash.confex.com/ash/2022/webpr…
#tweetorial 🧵
🚩AL & MM - Transcriptional patterns link common causal root with differing behaviours
(1/14)
➡️Light-chain amyloidosis (AL) and multiple myeloma (MM), are plasma cell (PC) malignancies with strikingly different clinical presentations 🥼🩺
➡️Success in🎯identifying these mechanisms has thus far been limited 👎
(2/14)
➡️Alameda et al define a “transcriptional atlas” of normal PCs, AL amyloidosis, MM, and MGUS, identifying 13 different transcriptional patterns linking distinct PC dyscrasias to subsets of normal developing PCs, with diagnostic 🔬and prognostic implications
👉A provisional entity in the 2016 World Health Organization classification of acute leukemia 🩸🩸
👉Gene expression 🧬signature similar to Ph-positive ALL but lacks the BCR-ABL1 translocation @NancyArthurPhD
➡️Originally defined by gene expression 🧬profiling in 2009 by 2 groups
👉Children's Oncology Group (COG) and St. Jude Children's Research Hospital (referred to as Ph-like ALL) 👉Dutch Childhood Oncology Group (referred to as BCR-ABL1-like ALL) – DCOG/COALL
👉The differences in the approaches are outlined in the figure; more on the gene expression 🧬 signatures and diagnostic conundrums later!
"VEXAS SYNDROME", a multidisciplinary team of researchers @genome_gov have identified this new disorder:
(1/8)
➡️Monogenic adult-onset autoinflammatory disease affecting males ♂️👨👦
(2/8)
➡️Caused by a mutation in the UBA1 gene 🧬 that encodes major E1 enzyme that initiates ubiquitylation
➡️Suggests postzygotic somatic mutation may be a more frequent cause of human disease👨
➡️Patients develop inflammatory symptoms🔥and hematological abnormalities🩸👇